Thyroid disorders in mental patients

Current Opinion in Psychiatry

Volumn 22, Issue 4, 2009, Pages 391-395

  Bunevicius, Robertas ^a  

^a KAUNAS UNIVERSITY OF MEDICINE   (Lithuania)

Author keywords

Cognition; Deiodinase; Depression; Mental retardation; Receptor; Thyroid hormone; Transport

Indexed keywords

LIOTHYRONINE; MONOCARBOXYLATE TRANSPORTER 8; PLACEBO; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THYROID HORMONE; THYROID HORMONE RECEPTOR; THYROXINE; TRICYCLIC ANTIDEPRESSANT AGENT;

BIPOLAR I DISORDER; BRAIN; BRAIN DEVELOPMENT; BRAIN NERVE CELL; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DEPRESSION; GENE MUTATION; GENETIC POLYMORPHISM; HORMONE METABOLISM; HORMONE RELEASE; HORMONE TRANSPORT; HUMAN; HYPOTHYROIDISM; LIOTHYRONINE BLOOD LEVEL; MAJOR DEPRESSION; MENTAL DEFICIENCY; MENTAL DISEASE; MENTAL PATIENT; NEUROSIS; REVIEW; RISK FACTOR; SIDE EFFECT; THYROID DISEASE; THYROTOXICOSIS; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL;

BRAIN; COGNITION DISORDERS; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; DNA MUTATIONAL ANALYSIS; HUMANS; IODIDE PEROXIDASE; MENTAL DISORDERS; MENTAL RETARDATION; MONOCARBOXYLIC ACID TRANSPORTERS; NEURONS; POLYMORPHISM, GENETIC; RECEPTORS, THYROID HORMONE; THYROID DISEASES; THYROID HORMONES;

EID: 67651011594     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/YCO.0b013e328329e1ae     Document Type: Review

References (34)

1. Bauer M, Goetz T, Glenn T, Whybrow PC. The thyroid-brain interaction in thyroid disorders and mood disorders. J Neuroendocrinol 2008; 20:1101-1114. Up-to-date review on mental effects of thyroid-brain interaction in thyroid disorders and in mood disorders supported by recent findings in molecular endocrinology.
2. Gereben B, Zeöld A, Dentice M, et al. Activation and inactivation of thyroid hormone by deiodinases: local action with general consequences. Cell Mol Life Sci 2008; 65:570-590.
3. Panicker V, Cluett C, Shields B, et al. A common variation in deiodinase 1 gene DIO1 is associated with the relative levels of free thyroxine and triiodothyronine. J Clin Endocrinol Metab 2008; 93:3075-3081.
4. Peeters RP, van der Deure WM, Visser TJ. Genetic variation in thyroid hormone pathway genes; polymorphisms in the TSH receptor and the iodothyronine deiodinases. Eur J Endocrinol 2006; 155:655-662.
5. Visser WE, Friesema EC, Jansen J, Visser TJ. Thyroid hormone transport in and out of cells. Trends Endocrinol Metab 2008; 19:50-56. Biological and clinical importance of thyroid hormone transport in and out of cells is reviewed with special attention to mutations in MCT8 that are associated with psychomotor retardation and elevated serum T3 concentration, indicating importance of MCT8 in brain development. (Pubitemid 351317898)
6. Sorensen HG, van der Deure WM, Hansen PS, et al. Identification and consequences of polymorphisms in the thyroid hormone receptor alpha and beta genes. Thyroid 2008; 18:1087-1094.
7. Williams GR. Neurodevelopmental and neurophysiological actions of thyroid hormone. J Neuroendocrinol 2008; 20:784-794. Comprehensive review of the traditional genomic mechanisms of thyroid hormone action mediated by thyroid receptors in the developing and in the mature brain is presented. Molecular and experimental data on thyroid hormone transport and metabolism in the brain are discussed.
8. Suzuki T, Abe T. Thyroid hormone transporters in the brain. Cerebellum 2008; 7:75-83.
9. Fuchs O, Pfarr N, Pohlenz J, Schmidt H. Elevated serum triiodothyronine and intellectual and motor disability with paroxysmal dyskinesia caused by a monocarboxylate transporter 8 gene mutation. Dev Med Child Neurol 2009; 51:240-244.
10. Frints SG, Lenzner S, Bauters M, et al. MCT8 mutation analysis and identification of the first female with Allan-Herndon-Dudley syndrome due to loss of MCT8 expression. Eur J Hum Genet 2008; 16:1029-1037.
11. Papadimitriou A, Dumitrescu AM, Papavasiliou A, et al. A novel monocarboxylate transporter 8 gene mutation as a cause of severe neonatal hypotonia and developmental delay. Pediatrics 2008; 121:e199-e202.
12. Sijens PE, Rödiger LA, Meiners LC, Lunsing RJ. 1H magnetic resonance spectroscopy in monocarboxylate transporter 8 gene deficiency. J Clin Endocrinol Metab 2008; 93:1854-1859.
13. Samuels MH. Cognitive function in untreated hypothyroidism and hyperthyroidism. Curr Opin Endocrinol Diabetes Obes 2008; 15:429-433.
14. Samuels MH, Schuff KG, Carlson NE, et al. Health status, mood, and cognition in experimentally induced subclinical thyrotoxicosis. J Clin Endocrinol Metab 2008; 93:1730-1736.
15. Hogervorst E, Huppert F, Matthews FE, Brayne C. Thyroid function and cognitive decline in the MRC Cognitive Function and Ageing Study. Psychoneuroendocrinology 2008; 33:1013-1022.
16. Tan ZS, Beiser A, Vasan RS, et al. Thyroid function and the risk of Alzheimer disease: the Framingham Study. Arch Intern Med 2008; 168:1514-1520. Prospective study of a large cohort of elderly population with long follow-up period has demonstrated that low and high thyrotropin concentrations were associated with an increased risk for the Alzheimer's disease in women but not in men. The absence of thyroid hormone concentrations prevented analysis of the role of overt versus subclinical thyroid dysfunction or low T3 syndrome for risk of Alzheimer's disease.
17. Williams M, Harris R, Dayan C, et al. Thyroid function and the natural history of depression: findings from the Caerphilly Prospective Study (CaPS) and a meta-analysis. Clin Endocrinol (Oxf) 2009; 70:484-492.
18. Frey A, Lampert A, Dietz K, et al. Thyrotropin serum concentrations in healthy volunteers are associated with depression-related personality traits. Neuropsychobiology 2007; 56:123-126. (Pubitemid 351340024)
19. Patten SB, Williams JV, Lavorato DH, et al. Major depression as a risk factor for chronic disease incidence: longitudinal analyses in a general population cohort. Gen Hosp Psychiatry 2008; 30:407-413.
20. Farmer A, Korszun A, Owen MJ, et al. Medical disorders in people with recurrent depression. Br J Psychiatry 2008; 192:351-355. (Pubitemid 351692379)
21. Stipcević T, Pivac N, Kozarić-Kovacić D, Mück-Seler D. Thyroid activity in patients with major depression. Coll Antropol 2008; 32:973-976.
22. Laske C, Zank M, Klein R, et al. Autoantibody reactivity in serum of patients with major depression, schizophrenia and healthy controls. Psychiatry Res 2008; 158:83-86.
23. Schultz K, Träskman-Bendz L, Petersën A. Transthyretin in cerebrospinal fluid from suicide attempters. J Affect Disord 2008; 109:205-208.
24. Sullivan GM, Mann JJ, Oquendo MA, et al. Low cerebrospinal fluid transthyretin levels in depression: correlations with suicidal ideation and low serotonin function. Biol Psychiatry 2006; 60:500-506.
25. Jokinen J, Samuelsson M, Nordström AL, Nordström P. HPT axis, CSF monoamine metabolites, suicide intent and depression severity in male suicide attempters. J Affect Disord 2008; 111:119-124.
26. Azorin JM, Kaladjian A, Adida M, et al. Factors associated with rapid cycling in bipolar I manic patients: findings from a French national study. CNS Spectr 2008; 13:780-787.
27. Baumgartner A. Thyroxine and the treatment of affective disorders: an overview of the results of basic and clinical research. Int J Neuropsychopharmacol 2000; 3:149-165. (Pubitemid 30429359)
28. Eker SS, Akkaya C, Sarandol A, et al. Effects of various antidepressants on serum thyroid hormone levels in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32:955-961. (Pubitemid 351609229)
29. Aronson R, Offman HJ, Joffe RT, Naylor CD. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry 1996; 53:842-848. (Pubitemid 26303624)
30. Altshuler LL, Bauer M, Frye MA, et al. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am J Psychiatry 2001; 158:1617-1622. (Pubitemid 32923653)
31. Cooper-Kazaz R, Lerer B. Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors. Int J Neuropsychopharmacol 2008; 11:685-699. (Pubitemid 351931816)
32. 3 supplementation of SSRI treatment. Although these findings should be considered preliminary, they potentially provided a means of identifying responders to a specific antidepressant treatment.
33. 3.
34. 3 in depressed patients treated with an SSRI may be related to improvement in brain bioenergetics assessed by phosphorus MRS.